Response to Comments: MolDX: Melanoma Risk Stratification Molecular Testing

This document records the response to comments and administrative changes (title revision and effective/notice dates) related to MolDX: DecisionDX-Melanoma (LCD L37725). The provided text does not contain clinical coverage criteria, indications, limitations, frequency limits, or documentation requirements for melanoma molecular testing. Manual review of LCD L37725 (DecisionDX-Melanoma) is required to extract the specific coverage criteria and billing/documentation rules.